Researchers belonging to the School of Public Health T.H.Chan from Harvard University (USA) tested in rodents how the use of an antibody designed to block AP2 improves the glucose mechanism and reduces liver steatosis.
This is explained by the labor director, Gokhan S. Hotamisligi: “Our study has enabled two important findings.First, he has found the critical role played by the AP2 hormone in the abnormal metabolism of glucose.
And secondly, it has shown that AP2 can be used as an effective target for the treatment of diabetes and, although potentially, other immunomethabolic diseases. ”
The research - published in the journal Science Translational Medicine - aimed to evaluate the effect of AP2 blocking through monoclonal antibodies specifically designed in the laboratory.And according to the results, one of these new antibodies not only significantly improved glucose regulation in two independent obesity models in mice, but also associated with a significant reduction in liver steatosis.
The authors were hopeful with the finding: "These monoclonal antibodies have the potential to become a first family of drugs to combat metabolic and immunomethabolic diseases associated with obesity", so they will continue to deepen the tests in the laboratory prior to theirUse in humans.
